Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 11/20 | 0.79 |
| ▸ | EED | O75530 | 2/20 | 0.79 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.79 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.79 |
| ▸ | RBBP7 | Q16576 | 2/20 | 0.79 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAT2A | P31153 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14739825 | 0.88 | EZH2 (0.84) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12499687 | 0.88 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10254825 | 0.86 | EZH2 (0.81) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10256831 | 0.85 | EZH2 (0.78) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10255896 | 0.84 | EZH2 (0.81) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL1695250 | 0.84 | EZH2 (0.81) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684487 | 0.84 | EZH2 (0.92) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10255659 | 0.84 | EZH2 (0.86) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684147 | 0.83 | EZH2 (0.91) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684468 | 0.83 | EZH2 (0.86) | EZH2EEDRBBP4SUZ12RBBP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| EP-2773754-B1 | Compounds for use in the treatment of T-cell mediated diseases | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-08-03 | — | — | EP | disclosed |
| US-20160074394-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2016-03-17 | — | — | US | disclosed |
| US-20160074394-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2016-03-17 | — | — | US | disclosed |
| US-20160074394-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2016-03-17 | — | — | US | disclosed |
| US-9242962-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242962-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242962-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20140256739-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2014-09-11 | — | — | US | disclosed |
| US-20140256739-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2014-09-11 | — | — | US | disclosed |
| US-20140256739-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2014-09-11 | — | — | US | disclosed |
| WO-2013067300-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067302-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074394-A1 | METHOD OF TREATMENT | EZH1, EZH2, SUV39H2 | EZH2 2/4885EED 15/4885RBBP4 430/4885 |
| US-20140256739-A1 | METHOD OF TREATMENT | EZH1, EZH2, SUV39H2 | EZH2 2/4885EED 15/4885RBBP4 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.